NextCure, Inc.
NASDAQ: NXTC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael S. Richman
- Employees
- 43
- Headquarters
- Beltsville, United States
- IPO year
- 2019
- Market cap
- $4.7M
- Website
- https://www.nextcure.com
Loading NXTC…
Loading profile data…Frequently asked questions about NXTC
What does NextCure, Inc. (NXTC) do?
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trial...
Where does NXTC trade?
NextCure, Inc. (NXTC) trades on the NASDAQ Global Select.
What sector is NXTC in?
NextCure, Inc. (NXTC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NextCure, Inc.?
Michael S. Richman is the chief executive officer of NextCure, Inc. (NXTC).
Where is NextCure, Inc. headquartered?
NextCure, Inc. is headquartered in United States.
Does NXTC pay a dividend?
NextCure, Inc. (NXTC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NXTC go public?
NextCure, Inc. (NXTC) completed its initial public offering in 2019.